Evaluation of the Renal Function in an Ultra-endurance Race.

Not Applicable

Completed

• Conditions: Renal Insufficiency, Acute
• Interventions: Other: INFERNAL Intervention

• Registration Number: NCT03136315
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

During ultra endurance events, athletes experience extreme physical and mental demands, sometimes at the limits of the adaptive response to human physiology. This is particularly true for the renal function, and some evidence for acute renal failure has already been shown, sometimes leading to dialysis. However, the precise mechanisms involved in acute renal failure in such ultra endurance races are not clearly elucidated.

The aim of our study is to estimate glomerular filtration rate from serum and urinary creatinine and cystitin C at the beginning and at the end of a 110 km ultra endurance race. Our hypothesis is that during the ultra endurance race, renal function may be injured, with a risk for the athlete.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-04
• Study First Submitted: 2017-04-21
• Study First Submitted QC: 2017-04-27
• Study First Posted: 2017-05-02
• Study Start: 2017-09-07
• Primary Completion: 2017-09-10
• Study Completion: 2017-09-10
• Last Update Submitted: 2017-09-11
• Last Update Posted: 2017-09-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• Age: At least 20 years old
• Athlete that is officially registered to the 110 km race (INFERNAL Trail des Vosges)
• Athlete informed by a member (MD) of the Medical Staff of the race.
• Athlete that gives and signes the informed consent to the research protocol

Exclusion Criteria

• Athlete with a known disease that needs the following medications:
• Medications influencing the renin-angiotensin-aldosteron system (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosteron receptor blockers)
• Diuretic drugs
• Anticoagulant drugs
• Non-steroidal anti-inflammatory drugs
• Athlete with a known thyroid disease (because of the influence on the serum cystatin level)
• Athlete with a know renal disease
• Athlete with a know inflammatory disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
INFERNAL Arm	INFERNAL Intervention	The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.

Primary Outcome Measures

Name	Time	Method
Glomerular filtration rate	30 minutes at baseline (09.07.2017), and 30 minutes at the end of the 110 km race (2 or 3 days after baseline)	The glomerular filtration rate will be calculated from the serum and urinary creatinine and cystatin C dosage

Trial Locations

Locations (1)

Stade des Perrey; 🇫🇷 Saint Nabord, Lorraine, France